Chronic Periaortitis, Tocilizumab Monotherapy
Conditions
Keywords
chronic periaortitis, Tocilizumab, treatment response, complete remission, partial remission
Brief summary
This is a prospective study to investigate the treatment response of Tocilizumab on patients with active chronic periaortitis (CP). Methods: patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study and accepted Tocilizumab monotherapy for 3 months. Endpoints: The primary endpoint is to investigate the treatment response of Tocilizumab; the secondary endpoints include the improvement of inflammatory markers, the frequency of adverse events.
Detailed description
Patients enrolled received intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months. Demographic and clinical features, laboratory findings and imaging examinations were recorded at baseline and during 3-month follow-up. Imaging improvement was converted into the ratio of perivascular soft tissues shrinkage by evaluating 2 dimensions of greatest change on computed tomography (CT) at baseline and after 3 months. Partial remission was defined as obtaining alleviation of symptoms and normalization of inflammatory markers including erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP), with shrinkage of soft tissue mass in imaging \<70%. Further, complete remission was defined as normalization of inflammatory markers accompanied by shrinkage of soft tissue mass ≥70%.
Interventions
intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. adults ≥ 18 years of age at time of informed consent; 2. meet clinical diagnostic criteria including (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP; 3. at active stage: clinical symptoms or organ involvement; a higher level of ESR and CRP than normal;
Exclusion criteria
1. Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded. 2. Combined with other autoimmune diseases. 3. Known immunodeficiency disorder. 4. Pregnancy, lactation, or planning to become pregnant within 6 months of the test. 5. Positive test for, or prior treatment for, hepatitis B or HIV infection. A positive test for hepatitis B is detection of hepatitis B surface antigen (HBsAg) or HBV-DNA. 6. Evidence of active tuberculosis (TB), including Chest X-ray and PPD. 7. Severe abnormal liver function or cardiac insufficiency. 8. Any reason the investigator think that should not attend this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| treatment response | three months | the rate of partial remission and complete remission after 3-month TCZ monotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the frequency of treatment related adverse events | three months | adverse events caused by TCZ during 3-month follow-up. |
| the improvement of inflammatory markers | three months | including erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP). |
Countries
China
Outcome results
None listed